Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 11 October 1991:
Vol. 254. no. 5029, pp. 285 - 288
DOI: 10.1126/science.1925584
Prev | Table of Contents | Next

Articles

Science, Vol 254, Issue 5029, 285-288
Copyright © 1991 by American Association for the Advancement of Science

articles

Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen

CY Wang, DJ Looney, ML Li, AM Walfield, J Ye, B Hosein, JP Tam, and F Wong-Staal

United Biomedical, Inc., Lake Success, NY 11042.

A titer for homologous viral neutralization activity (greater than 1:19,683) was observed after a 3.5-year immunization period with an octameric, branching peptide representing the principal neutralizing determinant (PND) of the human immunodeficiency virus-1IIIB envelope protein. Booster immunizations elicited persistent and potent antibodies in guinea pigs, exceeding responses produced by a conventional bovine serum albumin conjugate by 100-fold. Peptide length, central presentation of a conserved sequence, and inclusion of an upstream sequence contributed to immunogenicity. Titers (greater than 1:1,000) of heterotypic neutralizing antibodies also developed. Octameric PND peptides are a promising approach for an acquired immunodeficiency syndrome (AIDS) vaccine.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
A Heterologous Helper T-Cell Epitope Enhances the Immunogenicity of a Multiple-Antigenic-Peptide Vaccine Targeting the Cryptic Loop-Neutralizing Determinant of Bacillus anthracis Protective Antigen.
J. Oscherwitz, F. Yu, and K. B. Cease (2009)
Infect. Immun. 77, 5509-5518
   Abstract »    Full Text »    PDF »
Synthetic Peptide Vaccine Targeting a Cryptic Neutralizing Epitope in Domain 2 of Bacillus anthracis Protective Antigen.
J. Oscherwitz, F. Yu, J. L. Jacobs, T.-H. Liu, P. R. Johnson, and K. B. Cease (2009)
Infect. Immun. 77, 3380-3388
   Abstract »    Full Text »    PDF »
Towards Covalent Vaccination: IMPROVED POLYCLONAL HIV NEUTRALIZING ANTIBODY RESPONSE INDUCED BY AN ELECTROPHILIC gp120 V3 PEPTIDE ANALOG.
Y. Nishiyama, Y. Mitsuda, H. Taguchi, S. Planque, M. Salas, C. V. Hanson, and S. Paul (2007)
J. Biol. Chem. 282, 31250-31256
   Abstract »    Full Text »    PDF »
Identification of B- and T-Cell Epitopes within the Fibronectin-Binding Domain of the SfbI Protein of Streptococcus pyogenes.
K. Schulze, E. Medina, G. S. Chhatwal, and C. A. Guzman (2003)
Infect. Immun. 71, 7197-7201
   Abstract »    Full Text »    PDF »
Induction of anti-simian immunodeficiency virus cellular and humoral immune responses in rhesus macaques by peptide immunogens: correlation of CTL activity and reduction of cell-associated but not plasma virus load following challenge.
T. U. Vogel, B. E. Beer, J. zur Megede, H.-G. Ihlenfeldt, G. Jung, S. Holzammer, D. I. Watkins, J. D. Altman, R. Kurth, and S. Norley (2002)
J. Gen. Virol. 83, 81-91
   Abstract »    Full Text »    PDF »
Characterization of V3 Loop-Pseudomonas Exotoxin Chimeras. CANDIDATE VACCINES FOR HUMAN IMMUNODEFICIENCY VIRUS-1.
D. J. FitzGerald, C. M. Fryling, M. L. McKee, J. C. Vennari, T. Wrin, M. E. M. Cromwell, A. L. Daugherty, and R. J. Mrsny (1998)
J. Biol. Chem. 273, 9951-9958
   Abstract »    Full Text »    PDF »
Human Rhinovirus Type 14:Human Immunodeficiency Virus Type 1 (HIV-1) V3 Loop Chimeras from a Combinatorial Library Induce Potent Neutralizing Antibody Responses against HIV-1.
A. D. Smith, S. C. Geisler, A. A. Chen, D. A. Resnick, B. M. Roy, P. J. Lewi, E. Arnold, and G. F. Arnold (1998)
J. Virol. 72, 651-659
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)